Repligen (RGEN) to Release Earnings on Wednesday

Repligen (NASDAQ:RGEN) will be posting its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Repligen to post earnings of $0.29 per share for the quarter. Repligen has set its FY 2024 guidance at 1.420-1.490 EPS and its FY24 guidance at $1.42-1.49 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. During the same period in the previous year, the firm earned $0.68 EPS. Repligen’s quarterly revenue was down 16.6% compared to the same quarter last year. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

Shares of RGEN opened at $171.28 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The stock has a 50 day simple moving average of $186.62 and a 200 day simple moving average of $173.56. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The firm has a market capitalization of $9.56 billion, a PE ratio of 237.89, a P/E/G ratio of 5.16 and a beta of 1.02.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 in the last quarter. 1.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. KeyCorp boosted their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Stifel Nicolaus boosted their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus target price of $196.70.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.